- Home
- About
- Animal Owners
- Membership
- Services
- Contact us
< Back
Objectives:
Pulmonary carcinoma in dogs is commonly managed with surgical resection, but the role of adjuvant chemotherapy for grade II and III carcinomas remains undetermined. This study investigates the survival outcomes of adjuvant vinorelbine on dogs with grade II and III pulmonary carcinoma, compared to surgical resection alone.
Methods:
A multicentre retrospective study evaluated 56 dogs with histologically confirmed grade II and III pulmonary carcinoma. Thirty- six dogs treated with adjuvant vinorelbine post-surgery and 20 dogs managed with surgical resection only were included. Cox proportional hazard analysis was used to assess survival outcomes.
Results:
Univariable analysis identified vinorelbine (HR = 0.31, p < 0.001), clinical signs (HR = 1.93, p = 0.03), tumour grade (HR = 8.25, p < 0.001), resection margins (HR = 4.29, p = 0.01), lymph node involvement (HR = 1.97, p = 0.02), and comorbidities (HR = 0.42, p = 0.004) were associated with survival. Multivariable analysis demonstrated that vinorelbine (HR = 0.08, p < 0.001), tumour grade (HR = 40.4, p < 0.001), and comorbidities (HR = 0.34, p < 0.001) were predictors of survival. Dogs treated with adjuvant vinorelbine had a median survival time (MST) of 331 days (p<0.001) compared to those treated with surgery alone had a MST of 124 days (p < 0.001).
Conclusions:
These findings suggest that adjuvant vinorelbine may improve survival outcomes in dogs with grade II and III pulmonary carcinoma following surgical resection.
34th Annual Scientific Meeting proceedings
Stream:
|
Session:
Date/Time: 03-07-2025 (19:45 - 20:00) | Location:
Date/Time: 03-07-2025 (19:45 - 20:00) | Location:
Survival of Dogs Treated with Adjuvant Vinorelbine Following Surgical Resection of Grade II and III Pulmonary Carcinoma
Wong N1, Yu J1, Rajan S2, Brockley LK2
1Animal Referral Hospital Canberra, Canberra, Australia, 2Advanced Vet Care, Melbourne, Australia.
Objectives:
Pulmonary carcinoma in dogs is commonly managed with surgical resection, but the role of adjuvant chemotherapy for grade II and III carcinomas remains undetermined. This study investigates the survival outcomes of adjuvant vinorelbine on dogs with grade II and III pulmonary carcinoma, compared to surgical resection alone.
Methods:
A multicentre retrospective study evaluated 56 dogs with histologically confirmed grade II and III pulmonary carcinoma. Thirty- six dogs treated with adjuvant vinorelbine post-surgery and 20 dogs managed with surgical resection only were included. Cox proportional hazard analysis was used to assess survival outcomes.
Results:
Univariable analysis identified vinorelbine (HR = 0.31, p < 0.001), clinical signs (HR = 1.93, p = 0.03), tumour grade (HR = 8.25, p < 0.001), resection margins (HR = 4.29, p = 0.01), lymph node involvement (HR = 1.97, p = 0.02), and comorbidities (HR = 0.42, p = 0.004) were associated with survival. Multivariable analysis demonstrated that vinorelbine (HR = 0.08, p < 0.001), tumour grade (HR = 40.4, p < 0.001), and comorbidities (HR = 0.34, p < 0.001) were predictors of survival. Dogs treated with adjuvant vinorelbine had a median survival time (MST) of 331 days (p<0.001) compared to those treated with surgery alone had a MST of 124 days (p < 0.001).
Conclusions:
These findings suggest that adjuvant vinorelbine may improve survival outcomes in dogs with grade II and III pulmonary carcinoma following surgical resection.
This website uses cookies to improve your experience and for traffic analysis. If you continue, we’ll assume that you agree to the use of cookies as stated in our Cookie Policy.